Channels - Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma :: FRELIP Discovery

Similar Items: Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma

Quick Look
Potential of oncolytic viruses in the treatment of multiple myeloma
Quick Look
The Role of Genomics in the Development and Treatment of Multiple Myeloma: Understanding the Challenges and Opportunities
Quick Look
Defining High-Risk Disease Biology in Multiple Myeloma: A Narrative Review
Quick Look
Serum ATIC Expression as a Novel Diagnostic and Prognostic Biomarker in Multiple Myeloma Patients
Quick Look
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Quick Look
Burden of Disease, Treatment Patterns, and Healthcare Resource Utilization in Multiple Myeloma in the Middle East and North Africa Region: A Targeted Literature Review
Quick Look
Re: predictive modeling of treatment-related thyroid dysfunction and prognostic implication in advanced nasopharyngeal carcinoma with PD-1 inhibitors
Quick Look
Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity
Quick Look
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review Study
Quick Look
Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases
Quick Look
The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies
Quick Look
Biomarker‐based long‐term safety and efficacy of PD‐1/PD‐L1 inhibitors combined with chemotherapy in advanced gastroesophageal carcinomas: A systematic review and meta‐analysis
Quick Look
Use of histone deacetylase inhibitors (HDACis) in pancreatic ductal adenocarcinoma (PDAC): A narrative review
Quick Look
Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2
Quick Look
Evodiamine Inactivates NF-κB and Potentiates the Antitumor Effects of Gemcitabine on Tongue Cancer Both in vitro and in vivo [Retraction]
Quick Look
EXPRESSION OF CONCERN: DIMP53‐1: A Novel Small‐Molecule Dual Inhibitor of p53–MDM2/X Interactions with Multifunctional p53‐Dependent Anticancer Properties
Quick Look
Real‐World Survival Over 25 Years in Extensive‐Stage Small‐Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors
Quick Look
Clinical Efficacy and Security Analysis of CDK4/6 Inhibitors Combined with ET in Patients with HR+HER2− Advanced Breast Cancer
Quick Look
Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study
Quick Look
Efficacy and Safety of Regorafenib with or without Immune Checkpoint Inhibitors as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Systematic Review and Arm-Level Synthesis of Real-World Comparative Cohorts
Quick Look
Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study
Quick Look
A contemporary overview of multiple endocrine neoplasia syndromes: MEN syndromes 1–5 and beyond
Quick Look
Doxorubicin and Edelfosine Combo-Loaded Lipid–Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma [Retraction]
Quick Look
A case of ROS1‐rearranged lung adenocarcinoma in a young man with multiple serosal effusions: Diagnostic pitfalls in pericardial fluid cytology